38 employees
Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.
2010
$40M
from 2 investors over 2 rounds
Anokion raised $40M on September 11, 2019
Investors: Celgene
Anokion raised $38M on May 9, 2014
Investors: Versant Ventures